Oppenheimer & Co. Inc. Has $212,000 Position in Hologic Inc. (HOLX)
Oppenheimer & Co. Inc. reduced its position in shares of Hologic Inc. (NASDAQ:HOLX) by 3.1% during the second quarter, Holdings Channel reports. The institutional investor owned 6,127 shares of the company’s stock after selling 198 shares during the period. Oppenheimer & Co. Inc.’s holdings in Hologic were worth $212,000 as of its most recent SEC filing.
A number of other large investors also recently bought and sold shares of HOLX. Prudential Financial Inc. raised its stake in Hologic by 20.3% in the first quarter. Prudential Financial Inc. now owns 2,627,461 shares of the company’s stock worth $90,648,000 after buying an additional 444,115 shares in the last quarter. Ngam Advisors L.P. raised its stake in Hologic by 11.7% in the first quarter. Ngam Advisors L.P. now owns 134,353 shares of the company’s stock worth $4,636,000 after buying an additional 14,115 shares in the last quarter. WASHINGTON TRUST Co raised its stake in Hologic by 4.9% in the first quarter. WASHINGTON TRUST Co now owns 550,846 shares of the company’s stock worth $19,004,000 after buying an additional 25,550 shares in the last quarter. Pacad Investment Ltd. raised its stake in Hologic by 83.9% in the first quarter. Pacad Investment Ltd. now owns 51,949 shares of the company’s stock worth $1,792,000 after buying an additional 23,697 shares in the last quarter. Finally, Compton Capital Management Inc. RI raised its stake in Hologic by 22.0% in the first quarter. Compton Capital Management Inc. RI now owns 10,530 shares of the company’s stock worth $363,000 after buying an additional 1,900 shares in the last quarter. 94.51% of the stock is currently owned by institutional investors.
Hologic Inc. (NASDAQ:HOLX) traded down 1.06% on Friday, reaching $38.37. The company’s stock had a trading volume of 1,937,492 shares. The company has a market capitalization of $10.64 billion, a price-to-earnings ratio of 42.30 and a beta of 1.03. Hologic Inc. has a 52 week low of $31.84 and a 52 week high of $41.66. The firm’s 50 day moving average price is $38.36 and its 200-day moving average price is $35.88.
Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, July 27th. The company reported $0.51 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.48 by $0.03. Hologic had a return on equity of 26.25% and a net margin of 9.39%. The company earned $717.40 million during the quarter, compared to the consensus estimate of $703.66 million. During the same quarter in the prior year, the business earned $0.43 earnings per share. The company’s revenue was up 3.4% compared to the same quarter last year. On average, equities analysts predict that Hologic Inc. will post $1.94 EPS for the current year.
Several equities research analysts have recently weighed in on the company. RBC Capital Markets reissued a “sector perform” rating and set a $39.00 target price (up previously from $37.00) on shares of Hologic in a research report on Monday, August 1st. Piper Jaffray Cos. set a $44.00 target price on Hologic and gave the stock a “hold” rating in a research report on Sunday, August 28th. Barclays PLC raised Hologic from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $42.00 to $44.00 in a research report on Friday. Zacks Investment Research lowered Hologic from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. Finally, Royal Bank Of Canada raised their target price on Hologic from $37.00 to $39.00 and gave the stock a “sector perform” rating in a research report on Monday, August 1st. Seven analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $42.47.
In related news, Director Nancy Leaming sold 6,221 shares of the stock in a transaction dated Monday, July 11th. The stock was sold at an average price of $36.04, for a total value of $224,204.84. Following the completion of the transaction, the director now owns 55,053 shares of the company’s stock, valued at $1,984,110.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.84% of the stock is owned by corporate insiders.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.